Over the past several months, NIH has reissued parent funding opportunity announcements (FOAs) for compatibility with FORMS-E and accompanying policy changes, as announced in our October 4, 2017 article “Funding Opportunities Updated To Reflect January 25, 2018 Policy Changes.”
Last month, NIH reissued the small business innovation research (SBIR) and small business technology transfer (STTR) parent FOAs. To accommodate NIH’s new clinical trial policies, the SBIR and STTR parent FOAs were each split into two separate FOAs, one that accepts clinical trial applications and one that does not.
PA-18-574, Parent SBIR (R43/R44, Clinical Trial Not Allowed)
PA-18-575, Parent STTR (R41/R42, Clinical Trial Not Allowed)
PA-18-573, Parent SBIR (R43/R44, Clinical Trial Required)
PA-18-576, Parent STTR (R41/R42, Clinical Trial Required)
Of the four FOAs, NIAID supports only those two that do not allow clinical trials. Small business applicants who wish to propose clinical trial research in NIAID’s scientific areas of interest should use SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) to apply. Find more information about that FOA at Investigator-Initiated Clinical Trial Resources.
You can view NIAID’s scientific areas of interest in the PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA (beginning on page 46).
If you are not sure whether your research proposal constitutes a clinical trial, go to Does your human subjects research study meet the NIH Definition of a clinical trial?
For additional details on the SBIR/STTR Omnibus FOA reissuance, read the January 16, 2018 Guide notice.